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Short chain fatty acids (SCFA), principally acetate, propionate, butyrate and valerate, are produced in 
pharmacologically relevant concentrations by the gut microbiome. Investigations indicate that they exert 
beneficial effects on colon epithelia. There is increasing interest in whether different SCFAs have distinct 
functions which may be exploited for prevention or treatment of colonic diseases including colorectal cancer 
(CRC), inflammatory bowel disease and obesity. Based on experimental evidence, we hypothesised that odd-
chain SCFAs may possess anti-mitotic capabilities in colon cancer cells by disrupting microtubule (MT) 
structural integrity via dysregulation of β-tubulin isotypes. MT dynamic instability is an essential 
characteristic of MT cellular activity. We report a minimal deterministic model that takes a novel approach 
to explore the hypothesised pathway by triggering spontaneous oscillations to represent MT dynamic 
behaviour. The dynamicity parameters in silico were compared to those reported in vitro. Simulations of 
untreated and butyrate (even-chain length) treated cells reflected MT behaviour in interphase or untreated 
control cells. The propionate and valerate (odd-chain length) simulations displayed increased catastrophe 
frequencies and longer periods of MT-fibre shrinkage. Their enhanced dynamicity was dissimilar to that 
observed in mitotic cells, but parallel to that induced by MT-destabilisation treatments. Antimicrotubule 
drugs act through upward or downward modulation of MT dynamic instab ility. Our computational modelling 
suggests that metabolic engineering of the microbiome may facilitate managing CRC risk by predicting 




Colorectal cancer (CRC) is the fourth most common cancer and second leading cause of cancer-related death in the 
UK.1 Short chain fatty acids (SCFA) are closely associated with colon epithelia as by-products of anabolic 
fermentation by gut bacteria.2 The principle SCFAs in the human gut are acetate, propionate, butyrate and valerate. 
These differ in carbon chain lengths (2, 3, 4 & 5 carbons, respectively). Butyrate is the most researched to date for 
colon health. It is the preferred energy source for the colonocyte, a potent regulator of cell fate,3 particularly 
apoptosis,4,5 and is thought to be chemopreventive. SCFAs have been shown to induce acetylation of target 
proteins, either via histone deacetylation6,7 or by shifting the balance of acetyl-CoA reactions towards 
acetylation;6,7 however, the mechanistic details of their functions in colonocytes are unclear. Our previous 
empirical work and others6,8 suggested that carbon chain length may impact on their actions, with odd and even 
carbon-length SCFAs possessing distinct functions by virtue of different pathways in â-oxidation and entry into the 
TCA cycle.  
Microtubules (MT) are cytoskeletal proteins that perform many critical cellular functions. In addition to 
maintaining cell structure, motility, intra- and intercellular transport, they are central to accurate formation and 
control of the mitotic spindle during cell division. MT fibres are composed of typically 13 protofilaments arranged 
longitudinally, each of which is constructed from αβ-tubulin heterodimers arranged in a head-to-tail manner. This 
confers the MT fibre with polarity so that polymerisation primarily occurs at the plus end. During assembly, the α-
tubulin subunits are bound within the fibre and inaccessible to external proteins; conversely, the β-tubulin subunits 
are exposed on the surface enabling them to undergo post-translational modifications (PTM) and interact with 
microtubule associated proteins (MAP), including dynein and kinesin motor proteins. The arrangement of β-
tubulin isotypes along the fibre combined with their PTMs has been hypothesised to generate a tubulin code that 
may direct MT functions and regulate MT behaviour.9,10 In order to perform their molecular functions MTs require 
the ability to rapidly grow, shrink and change direction in response to cellular cues. These transitions are an 
essential characteristic of MTs and are termed dynamic instability. The accepted view of MT dynamic instability is 
the MT capping model.13 Briefly, phosphorylated αβ-tubulin dimers bind to the plus end of the MT fibre to form a 
protective tubulin-GTP cap. Immediately following polymerisation, the β-tubulin-GTP subunits undergo 
irreversible hydrolysis to their GDP form. Although this  provides the necessary energy to drive MT growth,14 β-
tubulin-GDP is unstable and the fibre will rapidly dissociate if the protective GTP cap is not sustained. This is 
termed catastrophe and occurs when the pool of αβ-tubulin-GTP subunits in the vicinity of the fibre tip falls below 
a critical concentration.15 Once released into the cytosol, β-tubulin-GDP subunits are free to rephosphorylate, 
restoring the critical concentration and enabling MT growth to resume, termed rescue. These actions are illustrated 
in Figure 1A. Experimental evidence on MT dynamics has primarily been derived from fluorescent tracking 
microscopy of growing and shrinking MTs in vitro.12,16-19 The life history of an MT within a cell can range from 
several minutes to hours and involves extended periods of slow growth, short periods of rapid shrinkage and time 
spent pausing. Each period of elongation and shortening can consist of multiple catastrophes and rescues (Fig. 
1B).12,19 Despite appearing random, MT dynamic instability is a tightly regulated and orchestrated process. 
Polymerisation of a β-tubulin GTP subunit to an MT fibre and its subsequent hydrolysis is a cooperative 
procedure. Suggested mechanisms include chemical and protein-protein interactions between β-tubulin GTP and 
GDP subunits;20 conformational changes arising from GTP hydrolysis;21 and facilitated diffusion. The latter 
mechanism postulated that αβ-tubulin dimers are transported towards the plus end of an MT fibre by virtue of 
fibre’s polarity; as such, the probability that a dimer encounters an MT will increase as the MT lengthens.22 
The β-tubulin superfamily comprises of six principle classes thought to have functional significance.23,24 Most β-
tubulin isotypes are species, tissue or cell type specific. Their relative proportions within an MT fibre can be 
regulated by upstream signalling events, suggesting they may influence MT functional activity.11 Consequently, 
disrupting the fine balance of β-tubulin isotypes can lead to aberrant tubulin behaviour and may have implications 
in the progression of colonic diseases, including CRC.11,12 
Our proteomic analyses investigated proteins differentially regulated in colon cancer cells by treatment with 
butyrate, propionate and valerate. The results identified several cytoskeletal proteins that were significantly 
dysregulated:25 all three SCFAs targeted keratin 19; butyrate and propionate targeted actin; and propionate 
primarily targeted keratins 8 and 18; however, only propionate and valerate significantly targeted β-tubulin 
isotypes β2c-, β3- and β1-tubulin. These findings were consistent with our high content analyses (HCA) that had 
revealed valerate and propionate were the most effective in inducing MT breakdown and G2/M cell cycle arrest, 
despite being weaker effectors in apoptotic functions.5,26 Whereas butyrate induces cytoskeletal breakdown via 
apoptosis,4,5 these observations suggested that propionate and valerate may act through different mechanisms. 
Based on this evidence, it was hypothesised that odd- and even-chain SCFAs possessed distinct and unique 
metabolic functions.  
SCFAs act by promoting post-translational acetylation of target proteins. Bioinformatic searches of Reactome and 
SABiosciences11,27,28 indicated that the activities of several transcriptional regulators (TR) associated with β2c-, 
β3- and β1-tubulin genes (RFX, PPAR, NSFR and NF-κB) could be altered by acetylation. Histone acetylation also 
induces chromatin remodelling to promote transcription of target genes and can itself be influenced by upstream 
acetylation events.29,30 These results suggested that treatment of colonocytes with SCFAs altered the regulation of 
specific genes, including overexpression of β2c- and β3-tubulin and suppression of β1-tubulin transcription via 
acetylation of NF-κB.31,32 Both β2c- and β3-tubulin have been implicated in MT destabilisation;11 although less is 
known about the role of β1-tubulin in MT dynamics.  
Computational modelling has contributed to a better understanding of MT functions21,33-36 and the biophysical 
details of MT dynamic instability. Various approaches have been adopted, including Monte Carlo simulations;21,33 
simplified coarse-grained stochastic models;35 one- and three-dimensional modeling;37 and models focusing on 
different types of lattices and MT fibre-fibre interactions.33,36 The term “structural plasticity” invokes mechanisms 
more dependent on the structural conformations of bound subunits than their chemical states.20 Simulated systems 
of dynamic MTs have also advanced understanding of their associations with MAPs, the collective behaviour of 
MTs and motors, and have been used to replicate mitotic events.38,39 The model of Bayley et al. (1990) was pivotal 
in demonstrating the validity of the lateral-cap model, in which â-tubulin-GTP assembly is a cooperative stochastic 
event that is fully coupled with â-tubulin hydrolysis.40 Their hypothesis was supported by Pedigo and Williams 
(2002) who showed that conformational changes arising from â-tubulin-GTP hydrolysis directly after association 
was best described using kinetic principles of lattice interactions.21 Computational models have been proposed as a 
basis for predicting the actions of antimicrotubule drugs (AMDs).40,41 This had particular relevance for our 
investigation which aimed to explore the links between SCFAs, transcriptional regulation of â-tubulin isotypes, 
MT integrity and performance, and the potential use of SCFAs in adjuvant therapies in CRC. 
A common approach to modelling systems of this nature is to use ordinary differential equations (ODEs). 
These present biological systems as continuous and deterministic and assume that randomness is not an 
important factor in the system of interest. An alternative approach is to use stochastic models if there is 
deemed to be inherent variability within the biological system; a stochastic approach will be used in 
scenarios whereby a small number of molecules are suggested to be involved in discrete random 
collisions, such as during the expression of a single gene. The main limitation of stochastic models is that 
they have a tendency to be computationally intensive, as reviewed in McAuley et al. (2013).42-44 In this 
study, we sought to develop a minimal deterministic model based on experimental evidence that might 
explain or validate our hypothesis:25 that different SCFAs imposed differential effects on the balance of β-tubulin 
isotypes and their impact on MT integrity. A comparison between the stochastic behaviour of MTs in vivo and in 










Figure 1. Qualitative, Stochastic and deterministic representations of MT dynamic instability. (A) (left) 
A growing MT fibre showing the protective cap (dark circles) formed from αβ-tubulin dimers with β-
tubulin-GTP subunits; (right) an MT fibre undergoing catastrophe showing rapidly dissociating dimers 
with hydrolysed β-tubulin-GTP subunits (white circles). (B) The stochastic nature of MT dynamic instability 
in vivo and in vitro showing the life history of a growing MT as a series of catastrophe and rescue events. 
(C) A deterministic representation of MT dynamic instability in silico showing the averaging effects of the 
ODEs in the model. 
 
2 Methods, kinetic theory and simulations 
2.1 Qualitative model and design 
The rationale underpinning the selection of a deterministic model made up of ODEs was based on our 
experimental observations. These had demonstrated that this system was deterministic and the inherent variability 
was negligible. The schematic diagram in Figure 2 shows the key events in the hypothesised pathway. Two 
scenarios are presented: the first represents untreated cells displaying normal MT behaviour (Fig. 2A); the second 
represents SCFA-treated cells promoting perturbation of MT dynamic instability (Fig. 2B). The first three 
reactions (k1–k3) are involved in the synthesis of the differentially regulated β-tubulin isotypes (β2c-, β3- and β1-
tubulin); the next three reactions (k4–k6) are involved in MT dynamic instability based on the capping model.13 
With the exception of the perturbation step, the two parts of the model are distinct; therefore, no feedback loop has 
been included between the synthesis of βeta in the first part and the concentration of free β-tubulin subunits 
(tuGTP) in the second part. This was based on the assumption that the total number of β-tubulin subunits (free and 
bound) in the system is fixed but the relative proportions of stabilising and destabilising isotypes can shift. 
Consequently, the net upregulation of the three targeted β-tubulin isotypes (βeta) will be compensated by a net 
downregulation distributed among the remaining β-tubulin isotypes. (Based on our experimental results, none of 
the other β-tubulin isotypes was individually significantly downregulated). 
 
The pathway in Figure 2B (treatment with odd-chain SCFAs) is described below: 
• [k1–k3]: Treatment with odd-chain SCFAs drives acetylation of the target transcriptional regulators (TR); the 
acetylated TRs induce histone acetylation at β2c-, β3- and β1-tubulin genes (denoted βeta); thereby enhancing 
or extending synthesis of these β-tubulin isotypes. 
• [k4–k6]: Free phosphorylated â-tubulin-GTP subunits co-operatively bind to the plus end of the MT fibre and 
are rapidly hydrolysed to their unstable â-tubulin-GDP form; dissociation of the MT fibre (catastrophe) 
releases the bound â-tubulin-GDP subunits back into the cytosol where they are re-phosphorylated, enabling 
MT re-polymerisation (rescue) to resume. 
• The cycle then repeats.  
 
The effect of raising the proportion of these three MT-destabilising β-tubulin isotypes in the system was to drive 
depolymerisation of the MT fibre, thereby inducing catastrophe. In contrast, untreated simulations or treatment 
with even-chain SCFAs (Fig. 2A) had little impact on the acetylation of target TRs, thereby preserving MT 
dynamic instability.  
 
 
Figure 2. Schematic diagram representing the hypothesised effects of SCFA treatments on microtubule 
dynamic instability in colon cancer cells. (A) Butyrate (an even-chain SCFA) has little or no impact on the 
regulatory pathway (k1→k3) leading to normal synthesis of the three target β-tubulin isotypes (βeta) relative to 
untreated cells. Therefore MT dynamic instability (k4→k6) remains unperturbed. (B) In contrast, treatment with 
propionate or valerate (odd-chain SCFAs) induces dysregulation of βeta leading to perturbation of MT dynamicity 
by promoting depolymerisation of the MT fibre (k6). Arrows show forward and backward reactions; round-ended 
arrows indicate the target reaction is promoted by the product of the preceding reaction; changes in the 
concentrations of reactants are represented by changes in the diameters of the circles. The following abbreviations 
are adopted: TR, transcriptional regulators; HST, histones at the target genes; βeta, the combined weighted fold-
change of β3-, β2c- and β1- tubulin isotypes; MT, the MT fibre; tuGTP and tuGDP, total free phosphorylated and 
hydrolysed β-tubulin subunits, respectively; ac refers to the acetylated forms of TR and HST; p indicates 
phosphorylation; SCFAcoeff, the SCFA-activation coefficient specific to the hypothesised pathway. 
 
The modelled reactions obeyed kinetic rules and the relationships between the reactants were based on published 
observables and experimental data.  Within the specifications of the modelled system, and due to the complexities 
of biological processes, each reaction in the pathway represented a number of intermediate sub-reactions. This 
approach of model reduction meant that the kinetic variables of the combined reactions could not be defined.45 
Reaction rates can also be altered by post-translational modifications.46 As a result, parameters were set within 
biologically feasible limits derived from similar reactions reported in curated biomodels.47 However, 
computational strategies have demonstrated that modelling can be successful in gaining valuable insights into 
biological mechanisms even under conditions where kinetic or reactant data are limited or unknown.48,49 
2.2 Initial concentrations of reactants 
The initial reactant concentrations are summarised in the Online Supplement (ESI, Table 1). Our proteomic data 
was used to define the steady state concentrations of βeta relative to untreated values, (1.07, 1.34 and 1.40 for 
butyrate, propionate and valerate, respectively). To match these values, the corresponding SCFA activation 
coefficients (SCFAcoeff) were manually adjusted to 1.2, 2.8, and 3.6, respectively. This is an accepted approach 
that has been described previously.39 The total concentration of tubulin in the system was set at 10.0 µM based on 
typical values reported in the literature.12,13,16,50 Although the concentrations of MTs, and bound and free β-tubulin 
subunits continually fluctuated, the overall concentration was assumed to be constant within the fixed volume of 
the in silico cell. Therefore, the initial concentrations could be arbitrarily set as MT = 5.5 µM; tuGDP = 3 µM; 
tuGTP 1.5 µM. These were informed estimates based on the nature of MT dynamic instability. Sensitivity analyses 
were performed to verify that the estimated values and assumptions were reasonable and appropriate, and to 
identify those parameters that would have the greatest impact of the model outcomes. 
2.3 Kinetic rate laws and ODEs 
The rate law interpretation was set as deterministic. The kinetic reactions, rate constants, rate laws and ODEs are 
summarised in the Online Supplement (ESI, Tables 2 and 3). The three steps of MT dynamic instability (β-tubulin 
phosphorylation, rescue and catastrophe; Fig. 2B) were inspired by Tyson’s two-species model of cell division that 
displays spontaneous oscillations within set constraints.51 This in turn had been based on the hypothetical model of 
a mitotic oscillator52 and theoretical Brusselator model of chemical oscillations.53,54 In this study we used a similar 
approach to construct a minimal oscillating model in which the key requirement was for cooperative/non-linear 
kinetics within the cycle.  
 
2.4 Simulations and output parameters 
The key parameters of MT dynamicity are growth and shrinkage periods and rates and catastrophe and rescue 
frequencies; Catastrophe frequency is defined as the number of transitions from growth to shrinkage relative to the 
total elongation time; rescue frequency is defined as the number of transitions from shrinkage to growth relative to 
the total shrinkage time.16,19 The time MTs spend pausing was beyond the scope of this model and not included in 
the analyses. As described earlier, an MT can undergo multiple sub-events of growth and shrinkage, catastrophes 
and rescues during its life history. These have been depicted as micro-oscillations. 
The ratios of catastrophe:rescue frequencies, growth:shrinkage rates and growth:shrinkage times were calculated 
from the temporal data in order for equivalent comparisons to be made against the wide range of experimental 
data.  
The simulations were undertaken in COPASI v4.7.55 The simulation times ranged from 0 to 600–1000 s and data 
were recorded at intervals of 0.5 s. This provided a sufficient number of oscillations at a sensitivity suitable for 
analysis. The MT dynamicity parameters were evaluated following an initial delay of 500 s to allow β-tubulin 
synthesis to reach steady state (Fig. 3A). 
3. Results 
3.1 MT dynamicity parameters for SCFA treatments in silico 
The inter-relationships between MT fibres and β-tubulin GTP and GDP subunits (MT, tuGTP and tuGDP, 
respectively; Fig. 3B) and were in agreement with experimental observations12,19: MT polymerisation commenced 
when the concentration of free tuGTP reached a critical concentration (cc); MT dissociation was triggered when 
the concentration of tuGTP fell below the cc; the subsequent decrease in MT concentration (representing length) 
was reflected by  an increase in the concentration of free tuGDP.  
 
 
Figure 3. Temporal simulations showing the relationships between microtubule fibres and subunits in the 
hypothesised pathway. (A) Treatment with propionate and valerate (odd-chain SCFAs) significantly promotes 
synthesis of target β-tubulin isotypes (βeta: β2c-tubulin, β3-tubulin, β1-tubulin); whereas butyrate has little 
influence on βeta synthesis relative to untreated cells. Steady state is achieved at approximately 500s; valerate 
treatment: triangles (upper curve); propionate treatment: diamonds (centre curve); butyrate treatment: circles 
(bottom curve); the simulation time is 1000 s. (B) The inter-relationships between MT fibres (MT, middle curve) 
and free β-tubulin GTP and GDP subunits (tuGTP and tuGDP, top and bottom curves, respectively): the rapid 
gain and slow decline in free tuGDP is reflected by a rapid loss and slow increase in free tuGTP and consequently 
rapid shrinkage (catastrophe) and slow growth (rescue) in MT fibres; (a) indicates the point of rescue; (b) and (c) 
denote the critical concentration of tuGTP at which the protective cap at the end of the MT fibre is established and 
lost, respectively. Simulation time, 500–525 s. 
 
The temporal simulations for MTs for each SCFA treatment are shown in Figure 4A. The mean periods of the 
micro-oscillations were approximately 20 s. This was consistent with published values in vitro and in vivo for 
fluorescently tagged MTs.12,19,56 Qualitative examination of the profiles showed there was little difference between 
MT dynamicity in untreated cells in silico and those treated with butyrate (Fig. 4A). In both cases, the cycle of 
dynamic instability persisted over the simulation time and the mean concentration of MTs was 94% for butyrate 
relative to untreated values. In contrast, the MT profiles for propionate and valerate treatments showed increasing 
dampening of the oscillations, reflecting suppression of MT dynamic instability, and a reduction in the mean 
concentrations of MTs to 74% and 71% relative to untreated values, respectively. Figure 4B shows the 
corresponding rate-profiles in untreated cells and valerate treated cells. These include the rates of concentration 
changes for MTs and free GTP and GDP β-tubulin subunits. Together, these results demonstrated that odd- and 
even-chain SCFAs induced distinct actions on MT dynamic instability. The odd-chain SCFAs effectively 
abolished MT dynamic instability in silico, reflecting dissociation of the fibres and loss of MT integrity in vitro, 
consistent with our experimental iTRAQ and HCA observations in HCT116 colon cancer cells. Comparisons 
between the simulated MT-dynamicity values for the three SCFAs relative to untreated values (Table 1) showed 
that the catastrophe frequencies were increased, the rescue frequencies decreased, the growth:shrinkage times 
increased and the growth:shrinkage rates decreased in the order butyrate to propionate to valerate, with valerate 
having the greatest effect. 
 
 
Figure 4. Temporal simulations showing MT dynamic behaviour under different SCFA treatments. (A) Micro-
oscillations depicting catastrophe and rescue events in simulated SCFA treatments during 60 s of the MT’s 
lifespan: (left to right) butyrate (even-chain, 4 carbons); propionate (odd-chain, 3 carbons); and valerate (odd-
chain, 5 carbons). There is little change in MT dynamicity between untreated and butyrate treated cells and MT 
dynamic instability persists over time; however, treatments with propionate and valerate reduce growth periods, 
increase shrinkage periods and suppress MT dynamic instability. (B) The rates of changes in MTs and free GDP 
and GTP β-tubulin (tuGDP and tuGTP) concentrations for untreated and valerate treated simulations show the 
predominance of second-order cooperative association in untreated MTs (left) and the shift towards first-order 
dissociation in valerate treated MTs (right). 
 
Table 1. Fold-changes in the MT-dynamicity parameters for simulated treatments with SCFAs relative to 
untreated values in silico. 
MT Dynamicity parameter Butyrate Propionate Valerate 
catastrophe frequency [s-1] 0.98 1.08 1.24 
rescue frequency [s-1] 0.97 0.83 0.72 
catastrophe:rescue frequency 1.01 1.29 1.73 
relative time growing 1.00 0.94 0.80 
relative time shrinking 1.01 1.21 1.39 
growth:shrinkage times 0.99 0.77 0.58 
growth rate [µM/min]  0.92 0.13 0.001 
shrinkage rate [µM/min]  0.91 0.10 0.000 
growth:shrinkage rates 1.01 1.29 1.45 
3.2 Comparisons between MT dynamicity parameters in silico and experimental data in vitro. 
In order to determine whether the modelled outcomes could plausibly be attributed to MT destabilising treatments 
in vitro, they were compared to experimental measurements of MT dynamicity parameters in cells at different 
phases or undergoing different treatments. Experimental observations can yield a wide range of values for MT 
dynamicity dependent on species, tissue or cell type and external conditions; however they tend to report similar 
trends and ratios. For this reason, data from two representative reports were selected for interphase and mitotic 
epithelial cells,19 and MT-destabilising and MT-stabilising treatments in epithelial cells12 to minimise 
compounding effects. The experimental values are summarised in the online supplement (ESI, Table 4). The 
histograms in Figure 5 indicate that MT dynamicity ratios in untreated and butyrate treated cells in silico most 
closely matched those in interphase cells in vitro for growth and shrinkage but were closer to stabilised-control 
cells for catastrophe and rescue frequencies (Fig. 5A). Whereas, propionate and valerate treated MTs in silico 
displayed similarities to both mitotic and destabilised MTs in vitro for growth and shrinkage times and rates, but 
only to MT-destabilising treatments for catastrophe and rescue frequencies (Fig. 5B). Both mitotic and 
depolymerising MTs are dynamically active; however, these simulations strongly suggested that colon cancer cells 
treated with odd-chain SCFAs undergo MT-destabilisation as opposed to enhanced mitosis. These results 
supported our proposition that odd-chain SCFAs at above physiological concentrations may act as anti-
microtubule agents  
 
 
Figure 5. Goodness of fit of model to empirical data. Comparisons between model predictions and published 
observations of MTs in vitro show that (A) simulations for untreated and butyrate (even-chain SCFA) treated MTs 
in silico most closely reflect those in interphase cells (I) for growth:shrinkage periods and rates in vitro, and 
control cells in stabilising experiments (C-s) for catastrophe:rescue frequencies; (B) propionate and valerate 
(odd-chain SCFAs) treated MTs in silico most closely reflect MTs undergoing destabilising treatments (Ds) in 
vitro for all three MT dynamicity ratios; although they bear close similarities to mitotic cells (M) for 
growth:shrinkage periods and rates, they exhibit highly different behaviour from mitotic cells undergoing 
catastrophe and rescue. [U, B, P, V: untreated, butyrate, propionate and valerate treatments in silico, 
respectively; I, M, Cs, Cd, St, Ds: interphase, mitotic, control cells for stabilising and destabilising treatments, 
stabilising and destabilising treatments in vitro, respectively]. 
 
3.3 Sensitivity analyses: Influences of initial concentrations and kinetic rate constants on model behaviour 
Sensitivity analyses were carried out using the generic sensitivity framework in COPASI to assess the impacts of 
the initial reactant concentrations and kinetic rate constants on the reaction fluxes and temporal concentrations of 
the reactants, respectively. The summarised and scaled results are given in the Online supplement (ESI Table 5) 
and shown graphically in Figure 6A. The parameters with the greatest influences upstream of MT dynamic 
instability (k1→k3) were the initial concentration of histones (HST) and the forward kinetic rate constant for 
synthesis (k3f) of βeta (the three targeted β-tubulin isotypes): a 10% increase in the initial concentration of HST 
resulted in complete loss of MT dynamicity (Fig. 6B, centre); whereas a 10% increase in the forward rate of βeta 
synthesis led to over-stabilisation of the MTs (Fig. 6B, right), effectively negating the destabilising effects of 
valerate treatment (Fig. 6B, left). The dynamicity control factor that had the greatest influence in the cycle of MT 
dynamic instability was the rate of rephosphorylation of free tuGDP subunits (k6) (Fig. 6A). 
 
 
Figure 6. Sensitivity analyses showing the effects of small changes in the initial model parameters on the 
overall outcome of the model simulations. The histograms show the summarised scaled sensitivities of the 
modelled system (y-axes) to changes in each of the initial reactant concentrations or kinetic reaction rates (x-axes) 
in (A) the βeta synthesis pathway and (B) the MT dynamic instability cycle. The dark coloured bars represent 
initial concentrations of the reactants; the pale coloured represent kinetic rates (k-rates). The results show that the 
initial concentration of histones (HST) and the forward rate of βeta synthesis (k3f) have the greatest influences on 
βeta synthesis; whereas the initial concentration of MTs and the rate of phosphorylation of free tuGDP (k6) have 
the greatest influences on MT dynamic instability. (C) Representative simulations of MTs undergoing valerate 
treatment showing the effects of 10% changes in the HST and k3f: (left) no change in either parameter; (centre) a 
10% changes in the initial histone concentration (HST) leads to complete loss of MT dynamicity; (right) a 10% 
change in the forward rate of βeta synthesis (k3f) leads to overstabilisation of MT fibres. The effects of small 
changes in k6 are not shown due to the inherent instability of the oscillatory system not directly linked to SCFA 
input. There is no perturbation in untreated systems. The simulation times are 500–600 s. 
 
4. Discussion 
Antimicrotubule drugs have proved highly successful in the treatment of multiple cancers and other 
diseases, such as motor neuron disease.57,58 The review by Jordan and Wilson (2004) describes the ability 
of AMDs to induce apoptosis via mitotic arrest by suppressing MT dynamic instability.59 It was also 
suggested that cancer cells may dysregulate expression of β-tubulin isotypes in order to enhance resistance 
to AMDs.60 To date, SCFAs have not been directly identified as antimitotic agents, and experimental 
investigations have primarily focused on their ability to induce cell death and subsequent cytoskeletal 
breakdown via mechanisms that include alterations in pro- and anti-apoptotic proteins and tumour 
suppressor genes through Sp1 and Bcl-2 family proteins.26,62 We previously reported that propionate and 
valerate, both odd-chain SCFAs, dysregulated the balance of β-tubulin isotypes towards those associated 
with MT depolymerisation, and that this was concurrent with impairment of MT structural integrity. To 
test the plausibility and potential implications of this hypothesis, we constructed a speculative model to 
explore the possible impact SCFAs might have on MT dynamic instability in colon cancer cells. The 
initial results showed that simulations of MT dynamic instability in untreated and butyrate treated cells in 
silico resembled MT behaviour observed in interphase or untreated control cells in vitro;19 whereas 
simulations of propionate and valerate treatments (odd-chain SCFAs) showed close similarities to MTs 
under destabilising treatments in vitro.12 The perturbation target for SCFA input in the model was set at 
the dissociation step of MT dynamic instability; therefore, increased levels of catastrophe relative to 
rescue had been anticipated. However, the key finding of this study was that the simulated outcomes were 
closer to those reported for MT-destabilising treatments in vitro than mitotic cells, despite both being 
associated with high levels of MT dynamicity. This demonstrated that propionate and valerate may 
possess anti-mitotic functions and suggested a potential role for odd-chain SCFAs as anti-mitotic agents, 
enabling AMDs to be administered at sub-optimal doses while maintaining efficacy and inhibiting 
resistance. 
5. Conclusions 
In combination with earlier experimental results,25 the model presented here supports the hypothesis that 
propionate and valerate at supraphysiological concentrations trigger an anti-mitotic pathway in colon 
cancer cells that is unique to odd-chain SCFAs: the simulations provoked changes in MT dynamicity 
parameters that closely paralleled trends reported in cells undergoing MT-destabilising treatments.12 This 
study has demonstrated that computational dynamic modelling can make a significant contribution to such 
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